Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC102 + Temozolomide in Recurrent Glioblastoma
NCT02395692Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of methoxyamine hydrochloride in glioblastoma (GBM) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 2 years. Started Dec 2015; status: terminated.
02
Drugs
methoxyamine hydrochloride
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02395692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395692.